August 31, 2016 06:43 AM EDT
R&D
News Briefing

Pro­to­cols: With Nin­laro sales suf­fer­ing, Take­da launch­es huge mul­ti­ple myelo­ma study; Medi­vir split­ting, spin­ning R&D in­to a sep­a­rate com­pa­ny

John Carroll

Editor & Founder

Take­da is rolling out a ma­jor new study in­volv­ing mul­ti­ple myelo­ma pa­tients. Re­searchers are re­cruit­ing 5,000 pa­tients to track their re­al world ex­pe­ri­ence in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times